Analysis on the Global Hormone Replacement Therapy Market 2019-2024 – Abbott, Bayer, Merck, Novartis, and Pfizer Hold the Largest Shares – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hormone
Replacement Therapy Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.

The market for hormone replacement therapy is expected to witness a CAGR
of approximately 6.5%, over the forecast period.

Certain factors that are positively affecting the market growth are
increasing awareness on post-menopausal issues among women, rise in drug
development with novel delivery systems, and hormonal imbalance
disorders with rising geriatric population.

Hormonal imbalance disorders, with an increase in the geriatric
population, is one of the major factors responsible for the growth of
the market studied. With various kinds of hormonal changes, the female
body predominantly gets affected by the natural process of aging,
leading to abnormalities and diseases. Some of the common problems
include weight gain, memory decline, fatigue, low libido, aging
appearance, and muscle loss.

The most frequently reported consequence of age-related hormonal changes
occurs in cases related to menopause. The global average onset age for
menopause among women is approximately 50 years. In women, by the age of
50 years and above, the production levels of estrogen and progesterone
decrease significantly. The decrease in production levels of estrogen
and progesterone are compensated by the pituitary gland, with the
increased production of follicle stimulating hormone (FSH).

This is physically manifested in women in the form of post-menopause
symptoms, which include flush. In the United States, up to 10% of women
are diagnosed with polycystic ovary syndrome (PCOS), nearly 6% of
married women below the age of 45 years suffer from infertility, and
nearly 8% men under the age of 45 years receive fertility treatment
during their lifetime.

These factors associated with age lead to the rising demand for HRT,
thus driving the market studied.

In Therapy Segment, Estrogen Replacement Therapy is Expected
to Show the Fastest Growth over the Forecast Period

The most common form of estrogen replacement therapy (ERT) is oral
medication. Besides, ERT is also available in the commercial market, in
the form of pills, patches, and suppositories.

The most prominently consumed oral ERT variants include conjugated
estrogens (Premarin), estradiol (Estrace), and Estratab. ERTs are an
effective treatment option for female patients suffering from menopause
symptoms. However, there are several side effects associated with the
usage of ERTs. Oral ERTs are associated with strokes, blood clots, and
some cases of cancer. These side effects have been well documented in
the form of moderate-severe adverse drug reactions (ADRs).

These ADRs are expected to cause some erosion in the popularity of ERTs.
However, their adoption rate is expected to increase over the forecast
period, globally, due to the increasing prevalence of hormonal imbalance
issues among the geriatric people and pregnant women.

United States Holds the Largest Share in the North American
Region

Rising geriatric population is one of the primary factors responsible
for the growth of the hormonal replacement therapy market in the United
States.

According to the National Institutes of Health (NIH), almost half of all
the postmenopausal women in the United States reported having used HRT
at least once in their life. The conjugated equine estrogens
(CEE)/bazedoxifene tablet, a combination of estrogen and a selective
estrogen receptor modulator, is available in the United States for
menopausal VMS treatment and osteoporosis prevention.

Three organizations, namely, the American College of Obstetricians and
Gynecologists, the North American Menopause Society (NAMS), and the
Endocrine Society, have produced guidelines on the use of HRT during
menopause. As of 2016, there were 15 producers of estrogens and eight
producers of progestins. In 2016, the top-selling HRT-based drug was
Premarin, with a market share greater than 50% among HRTs. Consequently,
Premarin became the fifth most prescribed drug in the country.

Overall, the market for HRT in the United States is scheduled for high
growth over the forecast period. The major drivers of this market are
expected to increase the adoption of HRT among women, for both
post-menopausal and menopause management.

Competitive Landscape

The market is consolidated. Several companies with the largest market
share are Abbott, Bayer, Merck, Novartis, and Pfizer. However, there are
efforts being made by new players to enter the hormone replacement
therapy market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Awareness on Post-menopausal Issues among Women

4.2.2 Rise in Drug Development with Novel Delivery Systems

4.2.3 Hormonal Imbalance Disorders with Rising Geriatric Population

4.3 Market Restraints

4.3.1 High Cost of Hormone Replacement Therapy

4.3.2 Substantial Risk of Cancer Associated with Hormone Replacement
Therapy

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Therapy

5.1.1 Estrogen Hormone Replacement

5.1.2 Growth Hormone Replacement

5.1.3 Thyroid Hormone Replacement

5.1.4 Testosterone Replacement

5.2 By Route of Administration

5.2.1 Oral

5.2.2 Parenteral

5.2.3 Other Routes of Administration

5.3 By Disease

5.3.1 Menopause

5.3.2 Hypothyroidism

5.3.3 Growth Hormone Deficiency

5.3.4 Other Diseases

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East & Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East & Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 Bayer AG

6.1.3 Eli Lilly and Company

6.1.4 F. Hoffmann-La Roche

6.1.5 Hisamitsu Pharmaceutical Co. Inc.

6.1.6 Merck KGaA

6.1.7 Mylan N.V.

6.1.8 Novartis AG

6.1.9 Novo Nordisk AS

6.1.10 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/z0b9eq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health, Sexual
and Reproductive Health Drugs